Drug Mechanism

FDA-Approved Drug

Indication

Percentage response drug

Percentage response placebo

Number needed to treat (NNT)

Microbiome

Rifaximin

IBS-D

43

34

11

Hypersensitivity and motility

Eluxadoline

IBS-D

27

17

10

Motility

Alosetron

IBS-D

51

36

7

Gut secretion

Lubiprostone

IBS-C

18

10

12.5

Linaclotide

IBS-C

34

14

5

Plecanatide

IBS-C

30

18

8